Challenges Of Iranian Clinicians In Dealing With COVID-19: Taking Advantages Of The Experiences In Wenzhou

Cell Journal

Seyed Mohammad Reza Hashemian¹  Yaser Tahamtani²  Yousef Gholampour³  Jin-San Zhang⁴  Chengshui Chen⁴  Xiaokun Li⁴  Mehdi Totonchi⁵  Fatemeh Amoozegar⁶ 

[1] Chronic Respiratory Diseases Research Center, National Research Institute of Tuberculosis and Lung Diseases (NRITLD), Shahid Beheshti University of Medical Sciences, Tehran, Iran;Department of Diabetes, Obesity and Metabolism, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran;Department of Internal Medicine, School of Medicine, Fasa University of Medical Sciences, Fasa, Iran;Department of Pulmonary and Critical Care Medicine, The First Affiliated Hospital of Wenzhou Medical University, China;Department of Stem Cells and Developmental Biology, Cell Science Research Center, Royan Institute for Stem Cell Biology and Technology, ACECR, Tehran, Iran;Noncommunicable diseases research center, Fasa University of Medical Sciences, Fasa, Iran;

关键词: anti-inflammatory drug;    antiviral drug;    covid-19;    diagnosis;    sars-cov-2;   

DOI  :  10.22074/cellj.2020.7604

来源: DOAJ

【 摘 要 】

The novel coronavirus has been spreading since December 2019. It was initially reported in Wuhan, Hubei province of China. Coronavirus disease 2019 (COVID-19) has currently become a pandemic affecting over seven million people worldwide, and the number is still rising. Wenzhou, as the first hit city out of Hubei Province, achieved a remarkable success in effectively containing the disease. A great record was also observed in Wenzhou for the clinical management of COVID-19 patients, leading to one of the lowest death rates in China. Researchers and clinical specialists proposed and formulated combined approaches such as computerized tomography (CT)- scans and molecular assays, as well as using both allopathic and traditional medications to mitigate its effects. Iranian and Chinese specialists and scientists had a communication in clinical, molecular and pharmaceutical aspects of COVID-19. A proper guideline was prepared according to the experiences of Chinese clinicians in managing the full spectrum of COVID-19 patients, from relatively mild to highly complex cases. The purpose of this guideline is to serve a reference in the hospital for specialists so that they may better diagnose cases and provide effective therapies and proposed antiviral and anti-inflammatory drugs for patients.

【 授权许可】

Unknown